Brother Enterprises (SZ:002562)2022-12-03 08:58Group 1: Vitamin K3 Insights - The production of Vitamin K3 is linked to chromium tanning agents; if the tanning agents are not strong, it negatively impacts Vitamin K3 production [2] - Current industry competition suggests limited potential for new entrants or expansions in Vitamin K3 production [2] - Rising costs due to poor downstream conditions for chromium tanning agents and increased import prices for chromium ore are expected to positively influence Vitamin K3 prices in the future [3] Group 2: Vitamin B5 and Market Position - As a new manufacturer, the company will follow market pricing trends for Vitamin B5 [3] Group 3: Strategic Industry Entry - The company has chosen to enter the iodine contrast agent market based on strategic considerations, including downstream customer overlap, existing channels, competitive landscape, and production technology [3] - A dedicated pharmaceutical division has been established to develop the iodine contrast agent business [3] Group 4: Future Planning - The company's future focus will be on raw materials, pharmaceuticals, and flavors/fragrances to reduce product cyclicality [3] - The company has recruited talent in the fragrance and pharmaceutical sectors and is working on core product identification and upstream/downstream planning [3] - Plans include accelerating the development of the Brother Pharmaceutical strategic base and exploring strategic partnerships, acquisitions, and mergers to extend the product value chain and enrich product structure [3]